홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Hydrogen Bromide → 5-((2R,4S)-2-(cyclohexyloxymethyl)piperidin-4-yl)isoxazol-3(2H)-one

HRID 1963509
노트
인쇄 미리보기

반응식

HRID 1963509 반응식
[CH:1]1([O:7][CH2:8][C@H:9]2[CH2:14][C@@H:13]([C:15]3[O:19][NH:18][C:17](=[O:20])[CH:16]=3)[CH2:12][CH2:11][N:10]2C(OC)=O)[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1.Br>>[CH:1]1([O:7][CH2:8][C@H:9]2[CH2:14][C@@H:13]([C:15]3[O:19][NH:18][C:17](=[O:20])[CH:16]=3)[CH2:12][CH2:11][NH:10]2)[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 260Hydrogen BromideHCID 68502091(2R,4S)-Methyl 2-(cyclohexyloxymethyl)-4-(3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-1-carboxylate

생성물 1

HCID 667326875-((2R,4S)-2-(cyclohexyloxymethyl)piperidin-4-yl)isoxazol-3(2H)-one수율 3.2%

실험 절차

(2R,4S)-Methyl 2-(cyclohexyloxymethyl)-4-(3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-1-carboxylate (190 mg, 0.56 mmol) was dissolved in hydrogen bromide (33% in acetic acid, 4.43 mL, 25.27 mmol) and stirred at room temperature for 16 h. The solvent was removed in vacuo and the residue purified by preparative HPLC (Instrument: FractionLynx II, Mobilphase: gradient 5-95% MeCN in 0.2% NH3, pH 10, Column: Xbridge Prep C18 5 μm OBD 19*150 mm) to yield 5-((2R,4S)-2-(cyclohexyloxymethyl)piperidin-4-yl)isoxazol-3(2H)-one (5 mg, 3%). 1H NMR (600 MHz, dmso) δ 1.03-1.25 (m, 6H), 1.32-1.48 (m, 2H), 1.55-1.68 (m, 2H), 1.70-1.90 (m, 4H), 2.56-2.66 (m, 1H), 2.68-2.79 (m, 2H), 2.99-3.06 (m, 1H), 3.06-3.83 (m, 3H), 5.70 (s, 1H). HRMS Calculated for [C15H24N2O3+H]+: 281.1865. Found: 281.1860

후처리

  1. customThe solvent was removed in vacuo
  2. customthe residue purified by preparative HPLC (Instrument: FractionLynx II, Mobilphase: gradient 5-95% MeCN in 0.2% NH3, pH 10, Column: Xbridge Prep C18 5 μm OBD 19*150 mm)

출처 및 근거

ORD 기록
ord-d09b1a7917c547bd872307ff80d31b41
출처 데이터셋
uspto-grants-2013_04
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08415378B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트